Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Stopped early · Phase 2

Conditions studied: Smallpox

In brief

The purpose of this study is to examine the safety and the effectiveness of a new vaccine for the prevention of the disease, smallpox.

Key facts

Study ID
NCT00053508
Run by
Sanofi Pasteur, a Sanofi Company
People needed
274
Starts
2002-09-01
Expected to finish
2003-09-01
Last updated by the study team
2014-01-22

Who can join

Age: 18 and older, up to 29. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.